Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.

Desale, Swapnil S

Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. [electronic resource] - Journal of controlled release : official journal of the Controlled Release Society Jun 2015 - 59-66 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

1873-4995

10.1016/j.jconrel.2015.02.001 doi


Animals
Anti-Bacterial Agents--administration & dosage
Benzoquinones--administration & dosage
Breast Neoplasms--drug therapy
Cell Line, Tumor
Cell Proliferation--drug effects
Chemistry, Pharmaceutical
Doxorubicin--administration & dosage
Drug Compounding
Drug Synergism
Female
Gels
HSP90 Heat-Shock Proteins--antagonists & inhibitors
Humans
Lactams, Macrocyclic--administration & dosage
Mice
Mice, Nude
Nanostructures--chemistry
Receptor, ErbB-2--genetics
Xenograft Model Antitumor Assays